Case number IPR2024-00107
Sun Pharmaceutical Industries Ltd. et al. v. Novo Nordisk A/S > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| May 28, 2024 | 16 | board | Download |
| May 28, 2024 | 3001 | board | Exhibit 3001 Download |
| May 22, 2024 | 15 | petitioner | PETITIONERS' REPLY TO PATENT OWNER'S FURTHER AUTHORIZED REPLY Download |
| May 20, 2024 | 14 | patent_owner | Patent Owner's Further Authorized Reply Download |
| May 20, 2024 | 2031 | patent_owner | EX2031 - Email Exchange Between Counsel for Petitioner and Counsel for Patent Owner Regarding Request To File Stipulation Download |
| May 16, 2024 | 1099 | petitioner | Download |
| May 16, 2024 | 13 | petitioner | Updated Exhibit List May 1 Download |
| Mar 29, 2024 | 12 | patent_owner | Patent Owner's Sur-Reply Download |
| Mar 29, 2024 | 2028 | patent_owner | EX2028 - Excerpt of Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Download |
| Mar 29, 2024 | 2029 | patent_owner | EX2029 - Excerpt of Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Download |
| Mar 29, 2024 | 2030 | patent_owner | EX2030 - Excerpt of Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Download |
| Mar 15, 2024 | 1098 | petitioner | Oral Order, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No. 22-294 (CFC) (D. Del. March 13, 2024) Download |
| Mar 15, 2024 | 11 | petitioner | PETITIONERS REPLY TO PATENT OWNERS PRELIMINARY RESPONSE Download |
| Feb 29, 2024 | 10 | patent_owner | Preliminary Response Download |
| Feb 29, 2024 | 2001 | patent_owner | EX2001 - Excerpt of Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Download |
| Feb 29, 2024 | 2002 | patent_owner | EX2002 - Petition for Inter Partes Review, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.1 (Mar. 16, 2023) Download |
| Feb 29, 2024 | 2003 | patent_owner | EX2003 - Declaration of Sayem Osman Download |
| Feb 29, 2024 | 2004 | patent_owner | EX2004 - Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 245 (D. Del. Oct. 31, 2023) Download |
| Feb 29, 2024 | 2005 | patent_owner | Download |
| Feb 29, 2024 | 2006 | patent_owner | EX2006 - Scheduling Order, Novo Nordisk Inc. v. Rio Biopharms., Inc., No. 1:22-cv-00294-CFC, Dkt. 22 (D. Del. June 30, 2022) Download |
| Feb 29, 2024 | 2007 | patent_owner | EX2007 - Excerpt of Transcript of Dec. 13, 2023 Claim Construction Hearing, Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., No. 23-101-CFC (D. Del. Dec. 13, 2023) Download |
| Feb 29, 2024 | 2008 | patent_owner | EX2008 - Claim Construction Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 148 (D. Del. July 25, 2023) Download |
| Feb 29, 2024 | 2009 | patent_owner | EX2009 - Joint Stipulation and Order Amending Scheduling Order, In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023) Download |
| Feb 29, 2024 | 2010 | patent_owner | EX2010 - Excerpt of Novo Nordisk's Third Amended Disclosures to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. July 28, 2023) Download |
| Feb 29, 2024 | 2011 | patent_owner | EX2011 - U.S. Patent No. 8,114,833 Download |
| Feb 29, 2024 | 2012 | patent_owner | EX2012 - Summons in a Civil Action, Sun Pharmaceutical Industries, Inc., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 7 (D. Del. Mar. 7, 2022) Download |
| Feb 29, 2024 | 2013 | patent_owner | EX2013 - Summons in a Civil Action, Sun Pharmaceutical Industries Ltd., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 8 (D. Del. Mar. 16, 2022) Download |
| Feb 29, 2024 | 2014 | patent_owner | EX2014 - Excerpt of Redacted Patent Owner's Response, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.30 (Jan. 17, 2023) Download |
| Feb 29, 2024 | 2015 | patent_owner | EX2015 - Excerpt of Novo Nordisk's Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. InDec. 21, 2022) [REDACTED] Download |
| Feb 29, 2024 | 2016 | patent_owner | EX2016 - Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022) Download |
| Feb 29, 2024 | 2018 | patent_owner | EX2018 - Excerpt of Defendants' Second Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Jan. 12, 2024) [REDACTED] Download |
| Feb 29, 2024 | 2019 | patent_owner | EX2019 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED] Download |
| Feb 29, 2024 | 2020 | patent_owner | EX2020 - Compilation of Defendants' Production Letters, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) [REDACTED] Download |
| Feb 29, 2024 | 2021 | patent_owner | EX2021 - Compilation of Rule 30(b)(1) Deposition Notices, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Download |
| Feb 29, 2024 | 2022 | patent_owner | EX2022 - Notice of Service for Defendants' Initial Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Download |
| Feb 29, 2024 | 2023 | patent_owner | EX2023 - Notice of Service for Defendants' Supplemental Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 6, 2023) Download |
| Feb 29, 2024 | 2024 | patent_owner | EX2024 - Stipulation for Extension of Time, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 309 (D. Del. Feb. 9, 2024) Download |
| Feb 29, 2024 | 2025 | patent_owner | EX2025 - February 26, 2024 Email from C. Ferenc to M. Raymond, re: IPR2024-00107 Download |
| Feb 29, 2024 | 2026 | patent_owner | EX2026 - Sun Pharmaceutical Industries Ltd.'s and Sun Pharmaceutical Industries Inc.'s Stipulation of Invalidity Contentions, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No. 22-cv-00294-CFC, Dkt. 275 (D. Del. Nov. 6, 2023) Download |
| Feb 29, 2024 | 2027 | patent_owner | EX2027 - Joint Stipulation and Order Extending Deadline for Certain Fact Discovery, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 305 (D. Del. Feb. 6, 2024) Download |
| Nov 29, 2023 | 9 | board | Notice: Notice filing date accorded Download |
| Nov 28, 2023 | 8 | patent_own | Joint Stipulation Regarding Petitioners' Motion for Joinder Download |
| Nov 21, 2023 | 7 | petitioner | Petitioner's Updated Mandatory Notice Download |
| Nov 9, 2023 | 4 | patent_own | Power of Attorney and Designation of Lead and Back-Up Counsel Download |
| Nov 9, 2023 | 5 | patent_own | Patent Owner's Mandatory Notices Download |
| Nov 2, 2023 | 1 | petitioner | Notice : Power of Attorney- Petitioner Download |
| Nov 2, 2023 | 1001 | petitioner | U.S. Patent No. 10,335,462 Download |
| Nov 2, 2023 | 1002 | petitioner | Prosecution history excerpts for U.S. Patent No. 10,335,462 Download |
| Nov 2, 2023 | 1003 | petitioner | Declaration of John Bantle, MD Download |
| Nov 2, 2023 | 1004 | petitioner | CV of John Bantle MD Download |
| Nov 2, 2023 | 1005 | petitioner | Declaration of William J. Jusko, Ph.D. Download |
| Nov 2, 2023 | 1006 | petitioner | CV of William J. Jusko, Ph.D. Download |
| Nov 2, 2023 | 1007 | petitioner | Declaration of Paul Dalby, Ph.D. Download |
| Nov 2, 2023 | 1008 | petitioner | CV of Paul Dalby, Ph.D. Download |
| Nov 2, 2023 | 1011 | petitioner | WO 2011/138421 Download |
| Nov 2, 2023 | 1012 | petitioner | Lovshin, Incretin-Based Therapies for Type 2 Diabetes Mellitus, 5 NATURE RE Download |
| Nov 2, 2023 | 1013 | petitioner | Clinical Trial No. NCT00696657 Download |
| Nov 2, 2023 | 1014 | petitioner | Clinical Trial No. NCT00851773 Download |
| Nov 2, 2023 | 1015 | petitioner | WO 2006/097537 Download |
| Nov 2, 2023 | 1016 | petitioner | U.S. Patent Application Pub. No. US2007/0010424 Download |
| Nov 2, 2023 | 1017 | petitioner | U.S. Patent No. 5,512,549 Download |
| Nov 2, 2023 | 1018 | petitioner | Banting, The Internal Secretion of the Pancreas, 7 J. LAB. CLINICAL MED. 25 Download |
| Nov 2, 2023 | 1019 | petitioner | Bell, Hamster Preproglucagon Contains the Sequence of Glucagon and Two Rela Download |
| Nov 2, 2023 | 1020 | petitioner | Bydureon prescribing information (Jan. 2012) Download |
| Nov 2, 2023 | 1021 | petitioner | Byetta prescribing information (Oct. 2009) Download |
| Nov 2, 2023 | 1022 | petitioner | Drab, Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status Download |
| Nov 2, 2023 | 1023 | petitioner | Drucker, Enhancing Incretin Action for the Treatment of Type 2 Diabetes, 26 Download |
| Nov 2, 2023 | 1024 | petitioner | Drucker, The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Download |
| Nov 2, 2023 | 1025 | petitioner | Glaesner, Engineering and Characterization of the Long-Acting Glucagon-Like Download |
| Nov 2, 2023 | 1026 | petitioner | Download |
| Nov 2, 2023 | 1027 | petitioner | Holst, Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from Download |
| Nov 2, 2023 | 1028 | petitioner | Holst, Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase IV in Download |
| Nov 2, 2023 | 1029 | petitioner | Jimenez-Solem, Dulaglutide, a Long-Acting GLP-1 Analog Fused with an Fc Ant Download |
| Nov 2, 2023 | 1030 | petitioner | Kim, Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Download |
| Nov 2, 2023 | 1031 | petitioner | Knudsen, GLP-1 Derivatives as Novel Compounds for the Treatment of Type 2 D Download |
| Nov 2, 2023 | 1032 | petitioner | Knudsen, Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Download |
| Nov 2, 2023 | 1033 | petitioner | Knudsen, Liraglutide, a GLP-1 Analogue to Treat Diabetes, in ANALOGUE-BASED Download |
| Nov 2, 2023 | 1034 | petitioner | Download |
| Nov 2, 2023 | 1035 | petitioner | Lund, Emerging GLP-1 Receptor Agonists, 16 EXPERT OP. ON EMERGING DRUGS 607 Download |
| Nov 2, 2023 | 1036 | petitioner | Mojsov, Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in the Gl Download |
| Nov 2, 2023 | 1037 | petitioner | Nielsen, Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Thera Download |
| Nov 2, 2023 | 1038 | petitioner | Seino, Dose-Dependent Improvement in Glycemia with Once-Daily Liraglutide w Download |
| Nov 2, 2023 | 1039 | petitioner | Download |
| Nov 2, 2023 | 1040 | petitioner | Download |
| Nov 2, 2023 | 1041 | petitioner | WO 03/002136 Download |
| Nov 2, 2023 | 1042 | petitioner | WO 91/11457 Download |
| Nov 2, 2023 | 1043 | petitioner | U.S. Patent App. Pub. 2004/0102486 Download |
| Nov 2, 2023 | 1044 | petitioner | Download |
| Nov 2, 2023 | 1045 | petitioner | Download |
| Nov 2, 2023 | 1046 | petitioner | Yun, Pharmacokinetic and Pharmacodynamic Modelling of the Effects of Glimep Download |
| Nov 2, 2023 | 1047 | petitioner | Tamimi, Drug Development: From Concept to Marketing!, 113 NEPHRON CLINICAL Download |
| Nov 2, 2023 | 1048 | petitioner | FDA Guidance for Industry, Exposure-Response Relationships - Study Design, Download |
| Nov 2, 2023 | 1049 | petitioner | International Conference on Harmonisation; Dose-Response Information to Sup Download |
| Nov 2, 2023 | 1050 | petitioner | Garber, Efficacy of Metformin in Type II Diabetes: Results of a Double-Blin Download |
| Nov 2, 2023 | 1051 | petitioner | Landersdorfer, Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellit Download |
| Nov 2, 2023 | 1052 | petitioner | Madsbad, An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonis Download |
| Nov 2, 2023 | 1053 | petitioner | Download |
| Nov 2, 2023 | 1054 | petitioner | Landersdorfer, Mechanism-Based Population Pharmacokinetic Modelling in Diab Download |
| Nov 2, 2023 | 1055 | petitioner | Landersdorfer, Mechanism-Based Population Modelling of the Effects of Vilda Download |
| Nov 2, 2023 | 1056 | petitioner | U.S. Patent No. 5,118,666 Download |
| Nov 2, 2023 | 1057 | petitioner | WO 2011/073328 Download |
| Nov 2, 2023 | 1058 | petitioner | Blonde, Comparison of Liraglutide Versus Other Incretin-Related Anti-Hyperg Download |
| Nov 2, 2023 | 1059 | petitioner | Murphy, Review of the Safety and Efficacy of Exenatide Once Weekly for the Download |
| Nov 2, 2023 | 1060 | petitioner | WO 2011/058193 Download |
| Nov 2, 2023 | 1061 | petitioner | U.S. Patent App. Pub. No. 2011/0166321 Download |
| Nov 2, 2023 | 1062 | petitioner | Download |
| Nov 2, 2023 | 1063 | petitioner | Kirillova, Results and Outcome Reporting in ClinicalTrials.gov, What Makes Download |
| Nov 2, 2023 | 1064 | petitioner | Monami, Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight Download |
| Nov 2, 2023 | 1065 | petitioner | Tasneem, The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) a Download |
| Nov 2, 2023 | 1066 | petitioner | Knudsen, Liraglutide: The Therapeutic Promise from Animal Models, 64(suppl Download |
| Nov 2, 2023 | 1067 | petitioner | U.S. Patent No. 8,536,122 Download |
| Nov 2, 2023 | 1068 | petitioner | U.S. Patent No. 8,129,343 Download |
| Nov 2, 2023 | 1069 | petitioner | REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso R. Gennaro ed., 20 Download |
| Nov 2, 2023 | 1070 | petitioner | Boylan, Parenteral Products, in MODERN PHARMACEUTICS (Gilbert S. Banker et Download |
| Nov 2, 2023 | 1071 | petitioner | U.S. Patent No. 6,284,727 Download |
| Nov 2, 2023 | 1072 | petitioner | U.S. Patent No. 5,164,366 Download |
| Nov 2, 2023 | 1073 | petitioner | U.S. Patent No. 6,458,924 Download |
| Nov 2, 2023 | 1074 | petitioner | WO 00/37098 Download |
| Nov 2, 2023 | 1075 | petitioner | U.S. Patent No. 7,022,674 Download |
| Nov 2, 2023 | 1076 | petitioner | ClinicalTrials.gov Background, CLINICALTRIALS.GOV, https://clinicaltrials.g Download |
| Nov 2, 2023 | 1077 | petitioner | Award: ClinicalTrials.gov, https://ash.harvard.edu/news/clinicaltrials.gov Download |
| Nov 2, 2023 | 1078 | petitioner | U.S. Patent App. Pub. No. 2004/0102486 Download |
| Nov 2, 2023 | 1079 | petitioner | NCT00167115, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NC Download |
| Nov 2, 2023 | 1080 | petitioner | NCT01933490, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NC Download |
| Nov 2, 2023 | 1081 | petitioner | Ozempic prescribing information (Oct. 2022) Download |
| Nov 2, 2023 | 1082 | petitioner | Scheduling Order, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No. 22- Download |
| Nov 2, 2023 | 1083 | petitioner | Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 3038 (M Download |
| Nov 2, 2023 | 1084 | petitioner | EMA, ICH Topic S 7 A Safety Pharmacology Studies for Human Pharmaceuticals Download |
| Nov 2, 2023 | 1085 | petitioner | ACS Publications, https://pubs.acs.org/toc/jmcmar/47/17; https://pubs.acs.o Download |
| Nov 2, 2023 | 1086 | petitioner | Download |
| Nov 2, 2023 | 1087 | petitioner | Prosecution history excerpts for U.S. Patent No. 9,764,003 Download |
| Nov 2, 2023 | 1091 | petitioner | Declaration of Melissa Weinberg, MD Download |
| Nov 2, 2023 | 1092 | petitioner | CV of Melissa Weinberg, MD Download |
| Nov 2, 2023 | 1093 | petitioner | Declaration of Craig Dyar, Ph.D. Download |
| Nov 2, 2023 | 1094 | petitioner | CV of Craig Dyar, Ph.D. Download |
| Nov 2, 2023 | 1095 | petitioner | Declaration of Alekha Dash, Ph.D. Download |
| Nov 2, 2023 | 1096 | petitioner | CV of Alekha Dash, Ph.D. Download |
| Nov 2, 2023 | 1097 | petitioner | Mylan Pharmaceuticals Inc., v. Novo Nordisk A/S, IPR2023-00724, Paper 10 (P Download |
| Nov 2, 2023 | 2 | petitioner | Motion : Joinder Download |
| Nov 2, 2023 | 3 | petitioner | Petition : as filed - Inter Partes Review of US Patent No. 10,335,462 Download |
